	US 12,318,477 B2
	Injectable and inhalable formulations
Peter Rands, London (GB); Carol Routledge, London (GB); Marie Layzell, London (GB); Ellen James, London (GB); Zelah Joel, London (GB); Tiffanie Benway, London (GB); and Meghan Good, London (GB)
Assigned to Cybin UK Ltd, London (GB)
Filed by CYBIN UK LTD, London (GB)
Filed on Nov. 18, 2022, as Appl. No. 18/056,771.
Claims priority of application No. 110143066 (TW), filed on Nov. 18, 2021; application No. PCT/EP2021/082227 (WO), filed on Nov. 18, 2021; application No. 2119021 (GB), filed on Dec. 24, 2021; and application No. PCT/EP2022/055324 (WO), filed on Mar. 2, 2022.
Prior Publication US 2023/0149293 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 31/4045 (2006.01); A61K 45/06 (2006.01)

CPC A61K 9/0019 (2013.01) [A61K 9/19 (2013.01); A61K 31/4045 (2013.01); A61K 45/06 (2013.01)]

21 Claims

1. A pharmaceutical formulation suitable for intramuscular injection, comprising a salt of a compound of Formula IB:

wherein:

n is 0;

R^1bis independently selected from —R^4b, —OH, —OR^4b, —O(CO)R^4b, monohydrogen phosphate, —F, —Cl, —Br or —I;

R^2bis C(^xbH)₃;

R^3bis C(^xbH)₃;

each R^4bis independently selected from C₁-C₄alkyl; and

each ^xbH, ^ybH and ^zH is independently selected from protium or deuterium;

and a Brønsted acid having a pKa of from about 3 to about 5;

a base agent, water, and optionally a buffer which is separate to the salt;

wherein the formulation has a pH of from about 5 to about 6.5, a concentration of the compound of Formula IB of about 10 mg/ml or greater as the freebase equivalent, and an osmolality of from about 250 to about 350 mOsm/Kg; and

wherein the formulation comprises a dose of the compound of Formula IB within a volume of 5 ml or less.